Our Pipeline
Our diverse pipeline is designed to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.
Our diverse pipeline is designed to meaningfully reduce the burden of vaccine-preventable diseases—and to make more diseases preventable.
SCB-1019 is a bivalent RSV-A/RSV-B vaccine candidate based on the prefusion-stabilized F (PreF) protein leveraging the validated Trimer-Tag platform and proprietary stabilizing PreF mutations.
In October 2024, Clover announced positive additional immunogenicity and safety data in older adult & elderly subjects from its Phase Ⅰ trial evaluating SCB-1019 – the company's non-adjuvanted bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate，compared head-to-head with GSK’s AS01E-adjuvanted RSV vaccine (AREXVY). This made Clover become the first vaccine company announced clinical trial results globally evaluating Head-to-Head comparison with a licensed RSV vaccine (Market-Leading AS01E-adjuvanted AREXVY represents high bar). Based on these positive Phase Ⅰ trial results, Clover plans to initiate clinical trials in 2025 evaluating SCB-1019 (non-adjuvanted bivalent RSV-A/B vaccine candidate) utilized in an RSV re-vaccination setting and as part of a respiratory combination vaccine.
AdimFlu-S (QIS) is a quadrivalent split inactivated vaccine intended for use in the prevention of influenza. AdimFlu-S (QIS) was approved by the China National Medical Products Administration in January 2022 for individuals aged three years and older.
Clover received Emergency Use Authorization (EUA) for SCB-2019 (CpG 1018/Alum) in China, and it was selected as the recommended vaccine in the "Implementation Plan for the Second Dose of Enhanced Immunization of COVID-19 Vaccine”.
Clover developed the SCB-2019 antigen, a stabilized trimeric form of the S-protein based on the original strain of the SARS-CoV-2 virus, and combined it with Dynavax's CpG 1018 advanced adjuvant and aluminum hydroxide (alum). Phase 2/3 data from 30,000+ participants across five countries showed that SCB-2019 (CpG 1018/Alum) achieved 100% efficacy against severe COVID-19 and hospitalization caused by all strains of SARS-CoV-2 circulating during the trial, and a potentially best-in-field safety profile. To date, these trials have shown that SCB-2019 (CpG 1018/Alum) elicited a robust neutralization of variants including Omicron.
Clover also developed XBB-Adapted SARS-CoV-2 vaccine candidate SCB-2023B based on the Trimer-Tag technology platform, and made a rolling regulatory submission to the Chinese regulatory authorities for this vaccine candidate.
The R&D development on Clover’s self developed rabies vaccine candidate SCB-1001 leveraging the Trimer-Tag platform is ongoing.
SCB-219M is an innovative thrombopoietin receptor agonist (TPO-RA) mimetic bispecific Fc-fusion protein, for the treatment of cancer patients with chemotherapy-induced thrombocytopenia (CIT).
We have announced positive Phase Ⅰ results for SCB-219M. A Phase Ⅰb trial evaluating repeated dosing of SCB-219M in CIT and CTIT patients is planned to initiate in 2024.
